+ Watch BLUE
on My Watchlist
Bluebird Bio, Inc is an interesting play for me, especially up, but I have been bullish biopharms before. It's always hard to value them, especially in early stage development, but I take some confidence from Bluebird being fairly new to the public arena. Long enough out that shorts can load and expirations for insiders are expiring, so much of the base can be truely formed. Overall, the volume is very low and the pattern is a bit of a mystery. Are the 5% swings caused from current holders selling slowing and being careful not to depress prices sub $20, or is it buyers looking for bargains and buying it back up. Overall decent build of institutional holdings. It's well below the $26 IPO, should have a solid base and has potential if successful. A good cash surplus. No need to dilute right away.The real plus is that I can get in 25% lower than Porte and ZZ! :)
ZZ likes it......
There's some companies I study fairly vigorously before I start nattering about them and some I don't. Bluebird falls into the latter category. There's not much I can do - I'm just one guy trying to follow 250 stocks plus I have two babies who think Dad's laptop is the greatest toy in the world. All I can say about Bluebird is that they're developing lentoviral vectors, which I believe are the vectors you use when you've given up other viral vectors for Lent. Bluebird has one trial in progress for a lentoviral gene therapy of beta thalassemia and another planned to begin in mid-2013, and they're planning to initiate a phase II/III trial of another lentoviral gene therapy for childhood cerebral adrenoleukodystrophy in late 2013.I happen to own 40 shares of Bluebird bought at the absolute all time high of 36 on July 17, courtesy of Portefeuille. I don't mean to razz him too much; that doesn't happen very often. The stock's been in a pretty nasty declining trend since then but I have a feeling things will pick back up before long. Hopefully by then I'll have had time to brush up a little on what this company actually does.
the future is... here
Negative book value but a P/C of only 0.07I don't remember ever seeing a valuation that low before in something this newly public. Has any Fool?
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions